C R Bard Inc (NYSE:BCR)‘s stock had its “hold” rating restated by stock analysts at Jefferies Group LLC in a note issued to investors on Thursday. They currently have a $317.00 price target on the medical instruments supplier’s stock. Jefferies Group LLC’s price objective would indicate a potential downside of 1.05% from the stock’s previous close.

A number of other brokerages have also recently commented on BCR. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $351.00 target price for the company in a report on Tuesday, June 6th. BidaskClub cut C R Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 target price on shares of C R Bard in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $285.67.

C R Bard (BCR) traded up 0.02% on Thursday, hitting $320.38. The stock had a trading volume of 457,962 shares. C R Bard has a 52-week low of $203.63 and a 52-week high of $324.58. The company has a market cap of $23.28 billion, a price-to-earnings ratio of 42.06 and a beta of 0.60. The company has a 50 day moving average price of $320.28 and a 200-day moving average price of $296.54.

C R Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C R Bard had a return on equity of 31.62% and a net margin of 14.26%. C R Bard’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.54 EPS. On average, equities research analysts predict that C R Bard will post $11.84 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/14/c-r-bards-bcr-hold-rating-reiterated-at-jefferies-group-llc.html.

In other news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Fundsmith LLP grew its position in shares of C R Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock valued at $633,996,000 after purchasing an additional 52,272 shares in the last quarter. Vivaldi Asset Management LLC purchased a new stake in shares of C R Bard in the second quarter valued at approximately $57,965,000. Leucadia National Corp purchased a new stake in shares of C R Bard in the second quarter valued at approximately $13,184,000. Credit Agricole S A grew its position in shares of C R Bard by 2.8% in the first quarter. Credit Agricole S A now owns 89,102 shares of the medical instruments supplier’s stock valued at $22,148,000 after purchasing an additional 2,425 shares in the last quarter. Finally, Ativo Capital Management LLC purchased a new stake in shares of C R Bard in the first quarter valued at approximately $2,504,000. Institutional investors and hedge funds own 79.34% of the company’s stock.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard Inc and related companies with MarketBeat.com's FREE daily email newsletter.